. 2025 Mar 18;11(1):e005237. doi: 10.1136/rmdopen-2024-005237

Table 2. Multiple logistic regression for duration of infliximab use in relation to different outcomes of cervical spine deformity at 10 years follow-up.

Variables in the model	Outcomes of cervical spine deformity	Sample size	Multivariable OR (95% CI)	P value
Duration of infliximab use (years)^*	Mild, moderate, or severe AAS>2 mm and/or SAS>2 mm	272	0.89 (0.81, 0.98)	0.02
Duration of infliximab use (years)+average DAS44 score^†	Mild, moderate, or severe AAS>2 mm and/or SAS>2 mm	272	0.87 (0.78, 0.96)	0.01
Duration of infliximab use (years)^*	Moderate or severe AAS≥3 mm in flexion	109	0.95 (0.81, 1.13)	0.58
Duration of infliximab use (years)+average DAS44 score^†	Moderate or severe AAS≥3 mm in flexion	109	0.95 (0.80, 1.13)	0.57
Duration of infliximab use (years)^*	Severe AAS≥5 mm in flexion or neutral	107	0.87 (0.61, 1.22)	0.41
Duration of infliximab use (years)+average DAS44 score^†	Severe AAS≥5 mm in flexion or neutral	107	0.87 (0.61, 1.22)	0.41

All three models for the three different outcomes of mild, moderate, or severe cervical spine deformity were adjusted for age at baseline, sex (male or female), anti-CCP positivity, rheumatoid factor positivity, and baselinebaseline DAS score.

^†

Adjusted for the previous multivariable model plus mean DAS during the 10--yearyear follow-up.

AASatlantoaxial subluxationDAS44Disease Activity ScoreSASsubaxial subluxation